Business
-
Aptar Pharma has “significantly increased” the production capacity at its facility in Eigeltingen, Germany for nasal delivery pumps for preservative free formulations, the company says, in order to meet continuously rising demand for preservative free… Read more . . .
-
Aradigm Corporation has agreed to sell 50 million shares of common stock at $0.12 per share to two existing shareholders, generating net proceeds of approximately $5.6 million after fees and expenses. According to Aradigm President… Read more . . .
-
Almirall’s Tudorza Pressair aclidinium bromide dry powder inhaler for the maintenance treatment of COPD is now available in the United States, where it is being marketed by Forest Laboratories. The twice-daily anticholinergic was approved in… Read more . . .
-
Aptar Pharma has announced the selection of a customized Landmark dose indicator for Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI. Flutiform is available for the treatment of asthma in Germany, the UK, and several other countries.… Read more . . .
-
The US Patent and Trademark Office has issued Patent number 8,324,266, titled “Compositions, Methods & Systems for Respiratory Delivery of Two or More Active Agents,” to Pearl Therapeutics. The patent covers formulation methods using the… Read more . . .
-
According to Consort Medical, Nicoventures, a subsidiary of the British American Tobacco Group, has awarded a contract to Consort’s Bespak Division “for the supply of an innovative nicotine inhalation product for use as a safer… Read more . . .
-
Lightlake Therapeutics, which is developing intranasal naloxone to treat eating disorders, has announced the appointment of board member Kevin Pollack as Chief Financial Officer. Pollack joined the board of directors in April 2012. Lightlake Chief… Read more . . .
-
Inhalation and particle engineering specialist Hovione and Swiss chemical development company Solvias have announced an agreement to collaborate on development and manufacturing of co-crystallized drugs. According to Hovione, “This strengthens Hovione’s expertise and experience in… Read more . . .
-
The FDA issued a letter to Alcon dated November 13, 2012 regarding a sales aid that the agency says overstates the efficacy of Alcon’s Patanase olopatadine hydrochloride nasal spray. In the four-page letter, the agency… Read more . . .
-
Fortical salmon calcitonin nasal spray manufacturer Unigene says that it is in danger of running out of cash before the end of the first quarter of 2013, due in part to the EMA’s July 2012… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.